Euglena Co Ltd

Euglena Co Ltd has a liquidity position characterized by a current ratio of 2.39 and cash and equivalents of ¥21.16 billion, which is partially offset by long-term debt of ¥2.77 billion. The company’s debt-to-equity ratio of 0.89 suggests moderate leverage, but its net income of -¥805 million indicates financial stress. Free cash flow of ¥3.28 billion provides some flexibility, though capital expenditures of -¥595 million suggest ongoing investment in operations. Profitability metrics show a return on equity of -2.6% and a return on assets of -1.11%, both significantly below the industry median for Food Processing. Gross profit of ¥35.03 billion represents 69.6% of revenue, but operating income of ¥2.64 billion is weak relative to revenue of ¥50.37 billion. The company’s operating margin of 5.2% is below the industry average, indicating inefficiencies in cost control or pricing power. The company operates through three segments: Healthcare, Biofuel, and Other. The Healthcare segment is the primary revenue driver, though specific revenue contributions by segment are not disclosed. The Biofuel segment is focused on R&D and production, while the Other segment includes organic fertilizers and genetic analysis. Geographic exposure is concentrated in Japan, with no material international revenue disclosed. This concentration increases vulnerability to domestic economic shifts. Growth trajectory is mixed. Revenue of ¥50.37 billion in the latest period shows a positive trend, but net income is negative. Analysts have assigned a mean price target of ¥400, with a single "Hold" recommendation and no "Buy" or "Strong Buy" ratings. The company’s free cash flow and operating cash flow of ¥3.28 billion and ¥5.19 billion, respectively, suggest some capacity for reinvestment or debt reduction, but capital expenditures remain a drag. Risk factors include liquidity risk due to negative net cash after subtracting total debt, and a weak return on equity. Dilution risk is assessed as low, with no near-term pressure expected. The company’s capital structure is stable, with no significant dilution sources identified in recent filings. However, the negative net income and weak ROIC suggest operational challenges that could require further financing. Recent events include a single analyst "Hold" recommendation and no price target dispersion, indicating limited analyst enthusiasm. No material earnings call transcripts or regulatory filings have been disclosed in the latest data, though the company’s ongoing R&D in biofuels and microalgae-based products may signal long-term strategic focus.